Ardelyx, Inc. (NASDAQ: ARDX) is a Healthcare company (Biotechnology) with a market capitalization of $799M. The Maz Rating grades it against the other companies in its sector.
Ardelyx, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.18, Ardelyx, Inc. trades at 1.7x sales and 4.8x book value. Over the last twelve months it generated about $471M of revenue and a net loss of $57M. It runs a gross margin of 94.3%, an operating margin of -7.7% and a net margin of -11.8%. It shows return on equity of -35.3%, return on invested capital of -7.8% and a free cash flow yield of -2.0%. On the balance sheet: a debt-to-equity ratio of 1.56 and a current ratio of 3.45. Over the past 52 weeks the share price ranged from $2.80 to $8.40, with a beta of 0.68.
Ardelyx, Inc. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 16 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Ardelyx, Inc. (ARDX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 30.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 33.8% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 30.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 33.8% / 33% · Receivables / Mkt Cap (36m) 11.1% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 30.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 33.8% / 33.33% · Receivables / Mkt Cap (24m) 11.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 42.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 49.3% / 33.33% · Receivables / Avg Assets (4Q) 16.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 43.2% / 33.33% · (Cash+ST Inv) / Total Assets 48.6% / 33.33% · (Cash+Recv) / Total Assets 64.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Ardelyx, Inc. (ARDX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Ardelyx, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
Ardelyx, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.